Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approves |
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency |
| gptkbp:brand |
gptkb:Vaxzevria
|
| gptkbp:clinicalTrials |
Phase III trials
published in peer-reviewed journals follow national health authority recommendations immunization against SARS-CoV-2 |
| gptkbp:community |
significant in controlling the pandemic
|
| gptkbp:contraindication |
fatigue
headache muscle pain nausea fever |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:dosageForm |
two doses
|
| gptkbp:evaluates |
approximately 76% after two doses
|
| gptkbp:expansion |
recommended after initial vaccination
|
| gptkbp:hasAccessTo |
prioritized for vulnerable populations
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vaxzevria
|
| gptkbp:interchanges |
with other COVID-19 vaccines
|
| gptkbp:lastProduced |
January 2021
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:AstraZeneca_COVID-19_vaccine
|
| gptkbp:notable_event |
required prior to vaccination
|
| gptkbp:notable_player |
collaborative international efforts
viral vector global vaccination campaigns reduction in COVID-19 cases adverse event reporting systems monitored post-approval assessed in real-world studies addressed through public education based on clinical trial results continues for long-term effects coordinated by governments performed by healthcare professionals requires cold chain management in_partnership_with_COVAX_initiative |
| gptkbp:productionCompany |
increased to meet demand
|
| gptkbp:providesSupportFor |
with various countries
|
| gptkbp:reproduction |
provided to recipients
|
| gptkbp:researchInterest |
ongoing for variants
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:safetyFeatures |
pharmacovigilance
|
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:supplyChain |
global distribution
|
| gptkbp:targets |
adults
elderly high-risk groups |
| gptkbp:technology |
recombinant DNA technology
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:usedFor |
COVID-19 prevention
|
| gptkbp:wasAffecting |
continuously evaluated.
|